Review
OSTEOPOROZUN MEDİKAL TEDAVİSİNDE KULLANILAN İLAÇLAR VE YAN ETKİLERİ Drugs Used for Medical Treatment of Osteoporosis and Their Side Effects
Abstract
ÖZET
Osteoporoz tedavisinde antirezorbtif ve anabolik ajanlar olmak üzere geniş bir aralıkta ilaç grubu vardır.
Tedavinin amacı, kemik formasyonunu arttırmak ve aşırı kemik rezorbsiyonunu önlemektir. Postmenopozal
osteoporoz ve diğer metabolik kemik hastalıklarında bifosfonatlar en yaygın kullanılan ilaçlardır. Bu nedenle
Bifosfonat (BF) yan etkilerine geniş yer verilip, kullanılan diğer osteoporoz ilaçlarından olan Denosumab ve
Teriparatin yan etkilerinden ve yakın takibinden detayları ile bahsedilecektir.
Anahtar Kelimeler; Osteoporoz; Kırık; tedavi; Yan etki
ABSTRACT
A wide range of medications including both antiresorptive and anabolic agents are available in the medical
treatment of osteoporosis. The aim of treatment is to increase bone formation and to inhibit excessive resorption.
Bisphosphonates are the most commonly used drugs in postmenopausal osteoporosis and other
metabolic bone diseases. Therefore, the side effects of bisphosphonate (BF) will be discussed extensively,
also the side effects and close monitoring of Denosumab and Teriparatide will be indicated in details.
Keywords: Osteoporosis; Fracture; treatment; Side effect
References
- 1. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. 2. Diagnosis and management of osteoporosis in postmenopausal women and oldermen in the UK: National Osteoporosis Guideline Group (NOGG) update 2013, Maturitas 75 2013; 392-396 3. Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010;21:325-43. 4. Delmas PD, Ensrud KE, Adachi JD, et al (Multiple Outcomes of Raloxifene Evaluation Investigators). Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617. 5. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41 6. Sorensen OH, Crawford GM, Mulder H et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6. 7. Miller PD: Bisphophonates: Pharmacology and use in the treatment of osteoporosis; In: Marcus R, Feldman D, Nelson DA, Rosen CJ editors. Osteoporosis 3. Ed vol 2 ch 74. Elsevier American Pres, San Diego USA; 2008. p. 1725-41. 8. Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin Interv Aging 2008;3:279-97. 9. Miller PD, Epstein S, Seddarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-13. 10. Emkey R, Delmas PD, Bolognese M et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clin Ther 2009;31:751-61
Year 2020,
Volume: 10 Issue: 1, 248 - 255, 25.03.2020
Abstract
References
- 1. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. 2. Diagnosis and management of osteoporosis in postmenopausal women and oldermen in the UK: National Osteoporosis Guideline Group (NOGG) update 2013, Maturitas 75 2013; 392-396 3. Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010;21:325-43. 4. Delmas PD, Ensrud KE, Adachi JD, et al (Multiple Outcomes of Raloxifene Evaluation Investigators). Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617. 5. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41 6. Sorensen OH, Crawford GM, Mulder H et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6. 7. Miller PD: Bisphophonates: Pharmacology and use in the treatment of osteoporosis; In: Marcus R, Feldman D, Nelson DA, Rosen CJ editors. Osteoporosis 3. Ed vol 2 ch 74. Elsevier American Pres, San Diego USA; 2008. p. 1725-41. 8. Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin Interv Aging 2008;3:279-97. 9. Miller PD, Epstein S, Seddarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-13. 10. Emkey R, Delmas PD, Bolognese M et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clin Ther 2009;31:751-61
There are 1 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Review |
| Authors | |
| Publication Date | March 25, 2020 |
| Published in Issue | Year 2020 Volume: 10 Issue: 1 |
Cite
Copyright © BOZOK Üniversitesi - Tıp Fakültesi